Cancer immunotherapy: The dark side of PD-1 receptor inhibition

Aya Ludin; Leonard I Zon

doi:10.1038/nature24759

Cancer immunotherapy: The dark side of PD-1 receptor inhibition

Nature. 2017 Dec 7;552(7683):41-42. doi: 10.1038/nature24759. Epub 2017 Nov 15.

Authors

Aya Ludin¹, Leonard I Zon^{1

2}

Affiliations

¹ the Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts 02138, USA.
² the Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, and at the Howard Hughes Medical Institute, Boston.

Abstract

Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
B7-H1 Antigen / antagonists & inhibitors
Humans
Immunotherapy*
Neoplasms
Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
B7-H1 Antigen
Programmed Cell Death 1 Receptor

Abstract

Publication types

MeSH terms

Substances

Grants and funding